The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market is expected to grow from USD 5.92 billion in 2025 to USD 8.55 billion in 2030, at a CAGR of 7.6%.
Highlights:
- 1Rising prevalence of idiopathic pulmonary fibrosis is driving increased demand for advanced diagnostic testing and early detection methods worldwide.
- 2Pharmacological treatments with pirfenidone and nintedanib are gaining widespread adoption for slowing disease progression and improving patient outcomes.
- 3Growing aging population and improved awareness are accelerating market expansion through higher diagnosis rates and treatment accessibility.
- 4North America continues leading regional growth with strong healthcare infrastructure supporting innovative diagnostics and specialized pulmonary care.
This research study examines the idiopathic pulmonary fibrosis diagnostic and treatment market based on various segments: type and geography. First, a brief overview of the market details key driving factors and challenges. Next, Porter's five forces model analyzes the idiopathic pulmonary fibrosis diagnostic and treatment market comprehensively. This is followed by industry value chain analysis, which determines the companies that are part of the different processes and contribute to various sectors.
The study also presents in-depth information concerning the development, trends, and industry policies and regulations affecting the idiopathic pulmonary fibrosis diagnostic and treatment market. Moreover, the research study analyzes the overall regulatory framework of the idiopathic pulmonary fibrosis diagnostic and treatment market, offering stakeholders a better understanding of the key factors influencing the overall market environment.
The idiopathic pulmonary fibrosis diagnostic and treatment market is a comprehensive and latest report. It provides vital market information to executives and interested stakeholders to enable them to get vital market information. The report also analyzes the competitive landscape and details strategies of key market players, and also plots them on our vendor matrix in four quadrants: leader, follower, challenger, and niche.
The scope and coverage of the idiopathic pulmonary fibrosis diagnostic and treatment market report is as below:
Idiopathic pulmonary fibrosis diagnostic and treatment market data tables and charts
Market outlook with sections on drivers, restraints, Porter’s, and industry value chain analysis
Market assessment by type into diagnostic testing, pharmacological drugs, and surgical treatment.
A 360° view of the demand for idiopathic pulmonary fibrosis diagnostic and treatment market solutions/services across different geographies (North America, South America, Europe, the Middle East and Africa, and the Asia Pacific), with further breakdown for key countries within those regions.
Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 5.92 billion |
| Total Market Size in 2030 | USD 8.55 billion |
| Forecast Unit | Billion |
| Growth Rate | 7.6% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Type, Drug Type, Route of Administration, End-Use |
| Companies |
|
| Customization Scope | 15% Free Customization included with purchase — Request Custom Breakdown → |
| Sample & Data Access | PDF Sample, Excel Databook & Analyst Briefing — Download Free Sample → |
Market Segmentation
By Type
By Drug Type
By Route Of Administration
By End-use
By Geography
Geographical Segmentation
- Middle East and Africa
Table of Contents
1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE
5.1. Introduction
5.2. Diagnostic Testing
5.3. Pharmacological Drugs
5.4. Surgical Treatment
6. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY DRUG TYPE
6.1. Introduction
6.2. Pirfenidone
6.3. Nintedanib
6.4. Others
7. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.2. Oral
7.3. Parenteral
8. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY END-USE
8.1. Introduction
8.2. Hospitals and Clinics
8.3. Ambulatory Surgical Centers
8.4. Others
9. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. United States
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. United Kingdom
9.4.2. Germany
9.4.3. France
9.4.4. Spain
9.4.5. Others
9.5. Middle East & Africa
9.5.1. Saudi Arabia
9.5.2. Israel
9.5.3. UAE
9.5.4. Others
9.6. Asia Pacific
9.6.1. Japan
9.6.2. China
9.6.3. India
9.6.4. South Korea
9.6.5. Indonesia
9.6.6. Thailand
9.6.7. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Roche Holding AG
11.2. Boehringer Ingelheim
11.3. AdAlta
11.4. FibroGen, Inc.
11.5. United Therapeutics
11.6. Galecto Biotech
12. APPENDIX
12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key benefits for the stakeholders
12.5. Research Methodology
12.6. Abbreviations
Frequently asked questions
What is the projected market size and growth rate for the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market from 2025 to 2030?
The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market is projected to grow from USD 5.92 billion in 2025 to USD 8.55 billion in 2030. This expansion reflects a Compound Annual Growth Rate (CAGR) of 7.6% over the forecast period, as detailed in this comprehensive research study.
How is the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market segmented by type in this report?
This report segments the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market by type into three key areas: Diagnostic Testing, Pharmacological Drugs, and Surgical Treatment. This segmentation offers a detailed assessment of the market's structure and the performance of each treatment modality.
Which geographic regions are analyzed in the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market report, and what are the key regional insights?
The report provides a 360° view of demand across North America, South America, Europe, the Middle East and Africa, and the Asia Pacific, with further breakdown for key countries within those regions. North America is highlighted as continuing to lead regional growth, driven by its strong healthcare infrastructure and support for innovative diagnostics and specialized pulmonary care.
What are the primary factors driving the growth of the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market according to the report?
The Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market's growth is primarily driven by the rising prevalence of idiopathic pulmonary fibrosis, leading to increased demand for advanced diagnostic testing and early detection. Widespread adoption of pharmacological treatments like pirfenidone and nintedanib, coupled with a growing aging population and improved awareness, are also accelerating market expansion.
What analytical frameworks and regulatory insights are included in the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market report?
The report provides a comprehensive analysis using Porter's five forces model and industry value chain analysis to understand market dynamics. Additionally, it presents in-depth information concerning development, trends, industry policies and regulations, and the overall regulatory framework influencing the market environment.
Cite this report
Knowledge Sourcing Intelligence. (Mar 2026). Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market - Strategic Insights and Forecasts (2025-2030). https://www.knowledge-sourcing.com/report/idiopathic-pulmonary-fibrosis-diagnostic-and-treatment-market